Our findings not only provide compelling evidence of the SOX17/NRF2 dysregulation in relation to CCRT resistance of ESCC, but also provide insights that help in the development of SOX17/NRF2-targeting treatment to overcome CCRT resistance. This evidence concerns the gene SOX17 and esophageal squamous cell carcinoma.